Drugs / Obinutuzumab
Obinutuzumab
also known as
GA-101 · GAZYVA · Gazyvaro · RO5072759 · AFUTUZUMAB · GA101 : Obinutuzumab · HUMAB CD20 · OBI · +5 more
Monoclonal antibody targets MS4A1
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | GAZYVA | — | 2014-12-24 – 2025-10-17 | fda.gov ↗ |
| Approved | EU (EMA) | Gazyvaro | — | 2014-07-22 | europa.eu ↗ |
| Approved | US (FDA) | GAZYVA | — | 2013-11-01 | fda.gov ↗ |
Trials 242 · started per year
today
US approved 2013
EU approved 2014
1
1
4
1
5
6
5
12
25
15
15
17
11
13
19
16
13
29
22
12
200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 137 trials | ||||||
| Phase 1 | NCT07548255 | Apr 2026 → Mar 2029 expected | mantle cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06824701 | Sep 2025 → Jan 2032 expected | B-cell non-Hodgkin lymphoma | University of Utah | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06351527 | Apr 2024 → Jun 2027 expected | neoplasm of mature B-cells | InnoCare Pharma Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06265220 | Apr 2024 → Aug 2027 expected | lupus nephritis, systemic lupus erythematosus | Artiva Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06547944 | Jan 2024 → Dec 2025 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05943496 | Oct 2023 → Jan 2027 expected | B-cell chronic lymphocytic leukemia | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05653271 | Jan 2023 → Mar 2026 | Burkitt lymphoma, follicular lymphoma, high grade B-cell lymphoma, marginal zone lymphoma +1 | Acepodia Biotech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05211336 | Apr 2022 → Jun 2024 overdue | diffuse large B-cell lymphoma of the central nervous system | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04599634 | Dec 2021 → Mar 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT04464798 | Nov 2020 → Jan 2023 | lymphoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT04073147 | May 2020 → Nov 2021 | primary central nervous system lymphoma | Klinikum Stuttgart | Terminated | No outcome recorded |
| Phase 1 | NCT04277637 | Mar 2020 → May 2027 expected | neoplasm of mature B-cells | BeOne Medicines | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04245722 | Mar 2020 → Sep 2023 | B-cell chronic lymphocytic leukemia | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT04023071 | Oct 2019 → Oct 2023 | B-cell neoplasm, acute myeloid leukemia | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT03432741 | Mar 2018 → Aug 2022 | Hodgkins lymphoma, breast adenocarcinoma, mycosis fungoides, nodal marginal zone B-cell lymphoma | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT03467373 | Mar 2018 → Dec 2024 | B-cell neoplasm, non-Hodgkin lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03113695 | Dec 2017 → May 2022 | Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma | University of California, San Diego | Completed | No outcome recorded |
| Phase 1 | NCT03198650 | Jun 2017 → Oct 2022 | B-cell chronic lymphocytic leukemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02992522 | Feb 2017 → Aug 2026 overdue | Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma | Beth Christian | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02877550 | Feb 2017 → Apr 2020 | follicular lymphoma | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02611908 | Jun 2016 → Nov 2019 | B-cell chronic lymphocytic leukemia | Michael Choi | Withdrawn | No outcome recorded |
| Phase 1 | NCT02569476 | Jan 2016 → Sep 2020 | B-cell neoplasm | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT02537613 | Dec 2015 → Mar 2020 overdue | B-cell chronic lymphocytic leukemia | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02586051 | Nov 2015 → Nov 2018 | end stage renal failure | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02453087 | Aug 2015 → Jul 2019 | B-cell non-Hodgkin lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02457598 | Jun 2015 → Sep 2024 | B-cell neoplasm | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT02417285 | May 2015 → May 2019 | diffuse large B-cell lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02292225 | Feb 2015 → Nov 2016 | chronic lymphocytic leukemia/small lymphocytic lymphoma | SecuraBio | Terminated | No outcome recorded |
| Phase 1 | NCT02324257 | Dec 2014 → Sep 2019 | cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02296918 | Dec 2014 → Aug 2021 | chronic lymphocytic leukemia/small lymphocytic lymphoma, prolymphocytic leukemia | Acerta Pharma BV | Completed | No outcome recorded |
| Phase 1 | NCT02220842 | Dec 2014 → Jan 2020 | lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02174172 | Aug 2014 → Nov 2019 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01685892 | Nov 2012 → May 2018 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01644253 | Sep 2012 → Feb 2020 | B-cell chronic lymphocytic leukemia, peripheral T-cell lymphoma, not otherwise specified | Aptevo Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT01680991 | Sep 2012 → Dec 2014 | B-cell neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01300247 | May 2011 → Jan 2013 | B-cell chronic lymphocytic leukemia | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00825149 | Feb 2009 → Nov 2015 | non-Hodgkin lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/230 trials | ||||||
| Phase 1/2 | NCT07520006 | May 2026 → May 2033 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Nurix Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07441954 | Mar 2026 → Dec 2027 expected | indolent B-cell non-Hodgkin lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06357676 | May 2025 → Nov 2027 expected | mantle cell lymphoma | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06592170 | Aug 2024 → Aug 2025 overdue | lymphoma | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06090539 | Dec 2023 → Oct 2027 expected | non-Hodgkin lymphoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05861050 | Aug 2023 → Feb 2027 expected | mantle cell lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04722601 | Sep 2021 → Mar 2023 | follicular lymphoma | University of Chicago | Terminated | No outcome recorded |
| Phase 1/2 | NCT04855695 | Jul 2021 → Jun 2027 expected | mantle cell lymphoma | Austin I Kim | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03930953 | May 2019 → Apr 2027 expected | non-Hodgkin lymphoma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03492125 | May 2018 → Nov 2023 | chronic lymphocytic leukemia/small lymphocytic lymphoma | MingSight Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 1/2 | NCT03135262 | Jun 2017 → Apr 2020 | diffuse large B-cell lymphoma, follicular lymphoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT02729896 | Nov 2016 → Sep 2018 | lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT02600897 | Mar 2016 → Dec 2021 | diffuse large B-cell lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT02611323 | Mar 2016 → Aug 2022 | non-Hodgkin lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT02631577 | Dec 2015 → Oct 2018 | follicular lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT02624986 | Dec 2015 → May 2019 | non-Hodgkin lymphoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT02596971 | Dec 2015 → Apr 2018 | diffuse large B-cell lymphoma, follicular lymphoma, susceptibility to | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT02558816 | Oct 2015 → Apr 2019 | mantle cell lymphoma | Nantes University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02315768 | Aug 2015 → Apr 2022 | B-cell chronic lymphocytic leukemia | University of California, San Diego | Completed | No outcome recorded |
| Phase 1/2 | NCT02427451 | Aug 2015 → Dec 2021 overdue | B-cell chronic lymphocytic leukemia | Kerry Rogers | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02406742 | Jul 2015 → Jul 2020 | B-cell chronic lymphocytic leukemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02391545 | Dec 2014 → Jan 2017 | follicular lymphoma | SecuraBio | Terminated | No outcome recorded |
| Phase 1/2 | NCT02257567 | Oct 2014 → Oct 2021 | lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT02229422 | Sep 2014 → Oct 2025 | chronic lymphocytic leukemia/small lymphocytic lymphoma | University of California, San Diego | Unknown | No outcome recorded |
| Phase 1/2 | NCT01995669 | May 2014 → Jan 2023 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, marginal zone lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01992653 | Nov 2013 → Dec 2018 | non-Hodgkin lymphoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02055820 | Nov 2013 → Jun 2017 | B-cell non-Hodgkin lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT01582776 | Oct 2012 → Jul 2018 | follicular lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 1/2 | NCT01691898 | Sep 2012 → Mar 2017 | diffuse large B-cell lymphoma, follicular lymphoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00517530 | Sep 2007 → Nov 2013 | lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2135 trials | ||||||
| Phase 2 | NCT07674810 | Dec 2026 → Apr 2027 expected | B-cell chronic lymphocytic leukemia | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07690891 | Oct 2026 → Dec 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Medical College of Wisconsin | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07624799 | Sep 2026 → Sep 2028 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | French Innovative Leukemia Organisation | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07710157 | Jul 2026 → Jun 2028 expected | minimal change disease | Medical University Innsbruck | Recruiting | No outcome recorded |
| Phase 2 | NCT07003295 | Jul 2026 → Aug 2027 expected | mantle cell lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT07514169 | Mar 2026 → Dec 2028 expected | large B-cell lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07233330 | Feb 2026 → Mar 2029 expected | idiopathic nephrotic syndrome | Mario Negri Institute for Pharmacological Research | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07218510 | Jan 2026 → Jun 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07299149 | Dec 2025 → Apr 2028 expected | follicular lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07261163 | Dec 2025 → Jul 2027 expected | mantle cell lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Show all 135 trials opens the full record — a long page | ||||||
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07163611 | Oct 2025 → Apr 2028 expected | membranous glomerulonephritis | Radboud University Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05786768 | Oct 2023 → Oct 2027 expected | idiopathic steroid-sensitive nephrotic syndrome | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 332 trials | ||||||
| Phase 3 | NCT06120673 | Oct 2025 → Jan 2028 | idiopathic membranous glomerulonephritis | The University of Queensland | Withdrawn | No outcome recorded |
| Phase 3 | NCT06943872 | Jun 2025 → Sep 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 3 | NCT06781944 | Oct 2024 → May 2028 expected | idiopathic membranous glomerulonephritis | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06428019 | Aug 2024 → Mar 2028 expected | B-cell chronic lymphocytic leukemia | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT06191744 | Feb 2024 → Nov 2037 expected | follicular lymphoma | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT05627557 | Mar 2023 → Sep 2025 overdue | idiopathic nephrotic syndrome | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05057494 | Sep 2022 → Jul 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05045664 | Jul 2022 → Sep 2027 expected | B-cell non-Hodgkin lymphoma | Heidelberg University | Recruiting | No outcome recorded |
| Phase 3 | NCT05197192 | Apr 2022 → May 2028 expected | B-cell chronic lymphocytic leukemia | German CLL Study Group | Recruiting | No outcome recorded |
| Phase 3 | NCT05100862 | Mar 2022 → Jul 2028 expected | marginal zone lymphoma | BeOne Medicines | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04702256 | Dec 2021 → Dec 2031 expected | lupus nephritis, systemic lupus erythematosus | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05058404 | Dec 2021 → Jul 2028 expected | follicular lymphoma | Fondazione Italiana Linfomi - ETS | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04963296 | Oct 2021 → Sep 2025 overdue | systemic lupus erythematosus | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04629248 | Jun 2021 → Dec 2025 overdue | idiopathic membranous glomerulonephritis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04269902 | Mar 2021 → Oct 2028 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT04608318 | Mar 2021 → Sep 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | German CLL Study Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04221477 | Aug 2020 → Aug 2024 overdue | lupus nephritis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04285567 | May 2020 → Mar 2024 | B-cell chronic lymphocytic leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03701282 | Feb 2019 → May 2028 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03406156 | Aug 2018 → Oct 2021 | chronic lymphocytic leukemia/small lymphocytic lymphoma | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02950051 | Dec 2016 → Feb 2024 | B-cell chronic lymphocytic leukemia | German CLL Study Group | Completed | No outcome recorded |
| Phase 3 | NCT02475681 | Jun 2015 → Feb 2019 overdue | B-cell chronic lymphocytic leukemia | Acerta Pharma BV | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01980875 | Apr 2015 → May 2016 | B-cell chronic lymphocytic leukemia | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT02264574 | Oct 2014 → Mar 2018 | B-cell chronic lymphocytic leukemia | Pharmacyclics LLC. | Completed | No outcome recorded |
| Phase 3 | NCT01905943 | Nov 2013 → Dec 2016 | B-cell chronic lymphocytic leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01659099 | Sep 2012 → Aug 2016 | diffuse large B-cell lymphoma | The Lymphoma Academic Research Organisation | Terminated | No outcome recorded |
| Phase 3 | NCT01287741 | Jul 2011 → Apr 2016 | diffuse large B-cell lymphoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT01332968 | Jul 2011 → Feb 2016 | non-Hodgkin lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01059630 | Apr 2010 → Sep 2014 | non-Hodgkin lymphoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02053610 | Dec 2009 → Aug 2013 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01998880 | Dec 2009 → Aug 2012 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01010061 | Dec 2009 → Jul 2012 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07611214 | Apr 2026 → Mar 2029 expected | lupus nephritis | Aurinia Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 4 | NCT07355699 | Nov 2025 → Sep 2027 expected | marginal zone lymphoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03817853 | Feb 2019 → Aug 2020 | follicular lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07126678 | Jul 2025 → Jul 2028 expected | follicular lymphoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT05950997 | Apr 2024 → May 2026 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT05797948 | Jul 2022 → Jun 2024 | B-cell non-Hodgkin lymphoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 78 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 128 trials | ||||||
| Phase 1 | NCT07107490 Background | Oct 2025 → Sep 2028 expected | small cell lung carcinoma | Chugai Pharmaceutical | Recruiting | No outcome recorded |
| Phase 1 | NCT06922604 Background | Jul 2025 → Jan 2029 | central nervous system non-hodgkin lymphoma | City of Hope Medical Center | Suspended | No outcome recorded |
| Phase 1 | NCT06916767 Background | Jul 2025 → Dec 2027 expected | B-cell chronic lymphocytic leukemia | Paolo Caimi, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT06624085 Background | Apr 2025 → Mar 2030 expected | lymphoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT06291220 Background | Jan 2025 → Jul 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06192888 Background | Jan 2024 → Jan 2028 expected | mantle cell lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05894447 Background | Nov 2023 → Dec 2025 | urothelial carcinoma | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 1 | NCT05364424 Background | Nov 2022 → Oct 2025 | diffuse large B-cell lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT05169515 Background | Oct 2022 → Sep 2029 expected | B-cell non-Hodgkin lymphoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT04970901 Background | Jun 2022 → Mar 2027 expected | B-cell non-Hodgkin lymphoma | ADC Therapeutics S.A. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05219513 Background | Feb 2022 → Jul 2024 | non-Hodgkin lymphoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT04826003 Background | Jul 2021 → Nov 2024 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04739813 Background | Jul 2021 → May 2026 overdue | Burkitt lymphoma, diffuse large B-cell lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04843904 Background | Apr 2021 → Jun 2025 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04657302 Background | Jan 2021 → Oct 2022 | lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04434196 Background | Dec 2020 → May 2024 | non-Hodgkin lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04551352 Background | Oct 2020 → Jul 2022 | cutaneous melanoma, mucosal melanoma, uveal melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04578600 Background | Oct 2020 → Dec 2023 | MALT lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, hairy cell leukemia +2 | Joseph Tuscano | Completed | No outcome recorded |
| Phase 1 | NCT04313608 Background | Jun 2020 → Oct 2021 | B-cell neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03983954 Background | Oct 2019 → Mar 2027 expected | cervical squamous cell carcinoma, colorectal cancer, endometrial cancer, esophageal cancer +14 | NeoTX Therapeutics Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03759184 Background | Jul → Dec 2019 | B-cell neoplasm, lymphoid leukemia | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT03866239 Background | May 2019 → Mar 2024 | colorectal cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT03539484 Background | Jul 2018 → Jul 2019 | cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT03369964 Comparator | Mar → Dec 2018 | non-Hodgkin lymphoma | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 1 | NCT03039114 Background | Feb 2017 → Mar 2021 | lymphoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02336048 Background | Jun 2015 → Sep 2018 | B-cell chronic lymphocytic leukemia | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT02100852 Background | Mar 2014 → Nov 2017 | chronic lymphocytic leukemia/small lymphocytic lymphoma | TG Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01671904 Background | Jan 2014 → Aug 2018 | B-cell chronic lymphocytic leukemia | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/214 trials | ||||||
| Phase 1/2 | NCT06634589 Background | Nov 2024 → Dec 2028 expected | B-cell neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06464185 Background | Apr 2024 → Mar 2026 overdue | B-cell non-Hodgkin lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05896163 Background | Aug 2023 → Apr 2026 | diffuse large B-cell lymphoma | Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT05673057 Background | Dec 2022 → May 2026 overdue | leukemia, myeloid neoplasm | Molecular Partners AG | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05533775 Background | Nov 2022 → Nov 2029 expected | B-cell non-Hodgkin lymphoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05159388 Background | Sep 2021 → Apr 2025 | cancer | Servier Bio-Innovation LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT04787042 Background | Aug 2021 → Jun 2025 overdue | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, renal cell carcinoma +1 | Simcha IL-18, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03980171 Background | Aug 2019 → Nov 2026 expected | follicular lymphoma | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04077723 Background | Aug 2019 → Mar 2027 expected | non-Hodgkin lymphoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03533283 Background | May 2018 → Oct 2026 expected | B-cell non-Hodgkin lymphoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03223610 Background | Feb 2018 → Dec 2026 expected | Burkitt lymphoma, diffuse large B-cell lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03010358 Background | Jul 2017 → Apr 2021 | B-cell prolymphocytic leukemia, Richter transformation, anemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +4 | Alexey Danilov, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT03075696 Background | Feb 2017 → Mar 2029 expected | non-Hodgkin lymphoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02529852 Background | Nov 2015 → Oct 2022 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 226 trials | ||||||
| Phase 2 | NCT07634289 Background | Dec 2026 → Dec 2031 expected | diffuse large B-cell lymphoma | Olivia Newton-John Cancer Research Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07711483 Background | Oct 2026 → Oct 2028 expected | B-cell non-Hodgkin lymphoma, large B-cell lymphoma | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07702851 Background | Sep 2026 → Aug 2030 expected | diffuse large B-cell lymphoma | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07599423 Background | Jul 2026 → Jul 2030 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07502872 Background | May 2026 → Dec 2029 expected | high grade B-cell lymphoma | Brown University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07613788 Background | May 2026 → Nov 2028 expected | large B-cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07326371 Background | Mar 2026 → Jul 2027 expected | diffuse large B-cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07231250 Background | Jan → Sep 2026 expected | diffuse large B-cell lymphoma | Li Zhiming | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07480850 Background | Jan 2026 → Jan 2028 expected | diffuse large B-cell lymphoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07240194 Background | Sep 2025 → Dec 2028 expected | large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07012980 Background | Jun 2025 → Jul 2026 overdue | diffuse large B-cell lymphoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06961500 Background | May 2025 → Nov 2030 expected | B-cell non-Hodgkin lymphoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06918015 Background | May 2025 → May 2028 expected | follicular lymphoma | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06867536 Background | Apr 2025 → Aug 2028 expected | relapsed/refractory diffuse large B-cell lymphoma | Liling Zhang | Recruiting | No outcome recorded |
| Phase 2 | NCT06567366 Background | Sep 2024 → Sep 2027 expected | large B-cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06474481 Background | Jul 2024 → Dec 2027 expected | — | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06043674 Background | Jan 2024 → Jan 2028 expected | B-cell chronic lymphocytic leukemia, Richter transformation | Christine Ryan | Recruiting | No outcome recorded |
| Phase 2 | NCT05833763 Background | Oct 2023 → Apr 2032 expected | mantle cell lymphoma | Australasian Leukaemia and Lymphoma Group | Recruiting | No outcome recorded |
| Phase 2 | NCT05848765 Comparator | Sep 2023 → May 2029 expected | follicular lymphoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 2 | NCT05478512 Background | Jul 2023 → May 2026 overdue | B-cell chronic lymphocytic leukemia | GIMEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04880863 Background | Oct 2021 → Jan 2024 | non-small cell lung carcinoma | NeoTX Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04703686 Background | Mar 2021 → Jan 2023 | indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, primary mediastinal large B-cell lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 2 | NCT04189588 Comparator | Mar → Nov 2020 | — | TerSera Therapeutics LLC | Completed | No outcome recorded |
| Phase 2 | NCT04934930 Background | Jan 2020 → Aug 2025 | follicular lymphoma | Meir Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03492775 Comparator | Dec 2017 → Nov 2021 | indolent B-cell non-Hodgkin lymphoma | Prof. Dr. Wolfgang Hiddemann | Completed | No outcome recorded |
| Phase 2 | NCT02867384 Comparator | Nov 2016 → Nov 2023 | chronic graft versus host disease | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT06284122 Comparator | Jun 2024 → Nov 2028 expected | follicular lymphoma | The Lymphoma Academic Research Organisation | Recruiting | No outcome recorded |
| Phase 3 | NCT06073821 Comparator | Nov 2023 → Feb 2032 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | BeOne Medicines | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06084936 Background | Oct 2023 → Aug 2027 expected | lymphoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT04796922 Background | Dec 2022 → Dec 2028 | follicular lymphoma, marginal zone lymphoma | Incyte Corporation | Withdrawn | No outcome recorded |
| Phase 3 | NCT04408638 Background | Feb 2021 → Mar 2028 expected | diffuse large B-cell lymphoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03836261 Comparator | Feb 2019 → Jan 2027 expected | B-cell chronic lymphocytic leukemia | Acerta Pharma BV | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03737981 Background | Jan 2019 → Jan 2025 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03462719 Comparator | Apr 2018 → Feb 2021 overdue | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02612311 Comparator | Nov 2015 → Feb 2023 | B-cell chronic lymphocytic leukemia | TG Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02242942 Background | Dec 2014 → Aug 2018 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
Press releases naming this drug 37 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-15 | Roche Global Development | FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy roche.com ↗ |
| 2026-04-21 | Roche Global Development | FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus roche.com ↗ |
| 2026-03-06 | Roche Global Development | New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus roche.com ↗ |
| 2026-02-16 | Roche Global Development | Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease roche.com ↗ |
| 2025-12-09 | Roche Global Development | European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis roche.com ↗ |
| 2025-11-03 | Roche Global Development | Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus roche.com ↗ |
| 2025-10-28 | Roche Global Development | Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome roche.com ↗ |
| 2025-10-20 | Roche Global Development | FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis roche.com ↗ |
| 2025-10-17 | Roche Global Development | CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis roche.com ↗ |
| 2025-03-05 | Roche Global Development | FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis roche.com ↗ |
| 2025-02-07 | Roche Global Development | New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis roche.com ↗ |
| 2024-09-26 | Roche Global Development | Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis roche.com ↗ |
| 2024-07-29 | AstraZeneca | Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukaemia in AMPLIFY Phase III trial astrazeneca.com ↗ |
| 2021-10-14 | Roche Global Development | Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma roche.com ↗ |
| 2021-06-12 | AbbVie | IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study abbvie.com ↗ |
| 2020-03-12 | Roche Global Development | European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia roche.com ↗ |
| 2019-11-11 | Roche Global Development | Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone roche.com ↗ |
| 2019-09-18 | Roche Global Development | FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis roche.com ↗ |
| 2019-06-04 | Roche Global Development | Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine roche.com ↗ |
| 2019-05-16 | Roche Global Development | Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia roche.com ↗ |
| 2019-03-07 | Roche Global Development | Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions roche.com ↗ |
| 2019-01-28 | AbbVie | AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Previously Untreated Patients abbvie.com ↗ |
| 2018-12-03 | AbbVie | IMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) abbvie.com ↗ |
| 2018-11-01 | Roche Global Development | Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities roche.com ↗ |
| 2018-10-17 | AbbVie | AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL) abbvie.com ↗ |
| 2018-06-15 | Roche Global Development | New long-term data confirm Roche's Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan roche.com ↗ |
| 2018-05-24 | AbbVie | IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint abbvie.com ↗ |
| 2017-11-17 | Roche Global Development | FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma roche.com ↗ |
| 2017-09-22 | Roche Global Development | Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma roche.com ↗ |
| 2017-07-21 | Roche Global Development | CHMP recommends EU approval of Roche’s Gazyvaro for people with previously untreated advanced follicular lymphoma roche.com ↗ |
| 2017-06-23 | Roche Global Development | Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma roche.com ↗ |
| 2016-12-05 | Roche Global Development | Roche’s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan roche.com ↗ |
| 2016-07-18 | Roche Global Development | Roche provides update on phase III study of Gazyva/Gazyvaro in people with previously untreated diffuse large B-cell lymphoma roche.com ↗ |
| 2016-06-16 | Roche Global Development | Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma roche.com ↗ |
| 2016-05-27 | Roche Global Development | Roche’s Gazyva/Gazyvaro showed superior progression-free survival compared to MabThera/Rituxan in people with previously untreated follicular lymphoma roche.com ↗ |
| 2016-04-29 | Roche Global Development | CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma roche.com ↗ |
| 2016-02-29 | Roche Global Development | FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma roche.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 324 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBINUTUZUMAB | “Targeting Bruton's tyrosine kinase (BTK), the novel BTK inhibitor zanubrutinib (highly selective, low toxicity) combined with obinutuzumab (enhanced antibody-dependent...” NCT07165769 ↗309“Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL” NCT03836261 ↗ “Obinutuzumab 1000 mg will be administered once by intravenous infusion on Cycle 1 Day 1 as pretreatment before glofitamab administration” NCT07702851 ↗ “Obinutuzumab is a type II anti-CD20 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity better than rituximab.” PMID 30068505 ↗ Aug 2018 “either Rituximab 375mg/m², intravenous infusion, Day 1 of each cycle, C1-C6; or Obinutuzumab 1000mg, intravenous infusion” NCT07355699 ↗ “2. Obinutuzumab: 1000mg intravenously on days 1, 8, and 15 of cycle 1 and on day 1 of subsequent 5 cycles;” NCT06918015 ↗ “Two doses of 1,000 mg IV obinutuzumab given prior to starting pembrolizumab and naptumomab estafenatox” NCT05894447 ↗ “The type II anti-CD20 antibody Obinutuzumab (OBINUTUZUMAB) has demonstrated remarkable activity” NCT03322865 ↗ “A single dose of obinutuzumab 1000 mg will be administered intravenously on Day 1 of Cycle 1.” NCT07012980 ↗ “Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1)” NCT05478512 ↗ “Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.” NCT03039114 ↗ “A single dose of obinutuzumab 1000 mg will be administered intravenously” NCT07514169 ↗ “PRS-344/S095012 Monotherapy or with pretreatment by obinutuzumab” NCT05159388 ↗ “intravenous (i.v.) application of obinutuzumab 1,000 mg on D1” NCT07231250 ↗ “Obinutuzumab with 2 x2 Gy involved site radiotherapy” NCT05045664 ↗ “G-Bendamustine = Obinutuzumab and Bendamustine” NCT05058404 ↗ “Obinutuzumab:1000mg, cycle 1 day 1(C1D1) ,IV.” NCT06464185 ↗ “Obinutuzumab pretreatment administered” NCT05673057 ↗ “GA101 - Obinutuzumab by IV infusion” NCT02229422 ↗ “GA101 : Obinutuzumab” NCT02558816 ↗ “Drug: Obinutuzumab” NCT04073147 ↗ |
| Known as | AFUTUZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743048 ↗ |
| Known as | GA-101 | “This open-label, multicenter study will evaluate the efficacy and safety of obinutuzumab [RO5072759 (GA101)] in combination with CHOP (Cyclophosphamide, Doxorubicin,...” NCT01414855 ↗18“Phase II Single-arm "Window-of-opportunity" Study of a Combination of Obinutuzumab (GA-101) and Venetoclax (ABT-199) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)” NCT02987400 ↗ “Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.” NCT03492775 ↗ “Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL” NCT03836261 ↗ “The CLL11 trial revealed an impressive improvement in efficacy with GA-101 (obinutuzumab) as compared to rituximab when combined with Chlorambucil.” NCT02758665 ↗ “Obinutuzumab (GA101) is a type II, glycoengineered anti-CD20 monoclonal antibody for the treatment of hematologic malignancies.” PMID 26659915 ↗ Dec 2015 “fixed doses of obinutuzumab (GA101) in relapsed/refractory follicular lymphoma patients” NCT01582776 ↗ “GA101 - Obinutuzumab by IV infusion” NCT02229422 ↗ “GA101 (Obinutuzumab)” NCT02320383 ↗ |
| Known as | GA101 : Obinutuzumab | “GA101 : Obinutuzumab” NCT02558816 ↗ |
| Known as | GAZYVA | “Experimental: GAZYVA, GAZYVARO(Obinutuzumab)” NCT05050214 ↗5“Obinutuzumab Injection [Gazyva]” NCT03341520 ↗ “Obinutuzumab Injection [Gazyva]” NCT06094881 ↗ “Obinutuzumab Injection [Gazyva]” NCT05995054 ↗ “Obinutuzumab 25 MG/ML [Gazyva]” NCT04082897 ↗ “Gazyva” NCT04189588 ↗ |
| Known as | Gazyvaro | “Obinutuzumab (Gazyvaro®) Obinutuzumab is a humanized glycoengineered type II anti-CD20 monoclonal antibody that recognizes the CD20 antigen present on normal and malignant B...” NCT06186648 ↗1“Experimental: GAZYVA, GAZYVARO(Obinutuzumab)” NCT05050214 ↗ |
| Known as | HUMAB CD20 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743048 ↗ |
| Known as | OBI | “Obinutuzumab (OBI), a next-generation fully humanized anti-CD20 monoclonal antibody” NCT07163611 ↗ |
| Known as | Obinutuzumab: Gazyva | “Obinutuzumab: Gazyva” NCT02100852 ↗ |
| Known as | OBZ | “Obinutuzumab (OBZ) is a type II anti-CD20 monoclonal antibody with a glycomodified Fc, approved in 2013 for the treatment of chronic lymphocytic leukemia.” NCT07268521 ↗ |
| Known as | R-7159 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743048 ↗ |
| Known as | RG-7159 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743048 ↗ |
| Known as | RO 5072759 HUMAB<CD20> | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743048 ↗ |
| Known as | RO5072759 | “This open-label, multicenter study will evaluate the efficacy and safety of obinutuzumab [RO5072759 (GA101)] in combination with CHOP (Cyclophosphamide, Doxorubicin,...” NCT01414855 ↗1“A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1” NCT03679455 ↗ |
| Action | Inhibit | “anti-CD20 monoclonal antibody” PMID 31050355 ↗ Jul 2019 |
| Modality | Monoclonal antibody | “Obinutuzumab (GA101) is a type II, glycoengineered anti-CD20 monoclonal antibody for the treatment of hematologic malignancies.” PMID 26659915 ↗ Dec 2015 |
| Route | Intravenous | “via intravenous infusion of obinutuzumab” NCT00517530 ↗ |
| Target | MS4A1 | “B-lymphocyte antigen CD20 binding agent” CHEMBL1743048 ↗ |